For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ PE-22-28
Illustration for PE-22-28

THE PEPSRADAR ENCYCLOPEDIA

PE-22-28

TREK-1 blockade in depression models

Research topics · Sources checked 2026-10-04

Read the studies ↓

PE-22-28 · KEY FACTS

Content updated · how dates work

Saved peptides

What is PE-22-28?

PE-22-28 is a seven-amino-acid peptide designed from spadin, a naturally occurring fragment of the sortilin propeptide. Its published evidence comes from cell-channel experiments and mouse behavior tests, not studies in people.

Biological role or research focus

TREK-1 blockade in depression models.

Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.

Role reference: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Names you may encounter

PE 22-28 · Spadin analog

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Seven-residue peptide designed from spadin, a sortilin-propeptide fragment; TREK-1 channel blocker in laboratory studies
Research focus
TREK-1 blockade in depression models
Featured evidence
Cell and animal study
Source check
October 4, 2026

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Quick answers

Is PE-22-28 FDA approved?
No. No FDA-approved drug contains PE-22-28. Source ↗
Is PE-22-28 safe?
Unapproved spadin-derived peptide tested only in cells and mice; there are no published human safety studies, so its risks are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is PE-22-28 banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Animal / mixed laboratory research
StudyTypePopulation / model
Shortened spadin analogs in TREK-1 cells and mouse depression models (2017)Cell and animal studyCell lines expressing human TREK-1, mouse cortical neurons, and mice in behavioral depression models.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Cell and animal study · 2017

Shortened spadin analogs in TREK-1 cells and mouse depression models

What did this publication test, and what did it find?

Population / model
Cell lines expressing human TREK-1, mouse cortical neurons, and mice in behavioral depression models.
Study design
Patch-clamp channel experiments, then mouse forced-swim and novelty-suppressed feeding tests, neurogenesis and synapse-marker measurements, and duration-of-action comparisons with spadin.
Main finding
The authors reported stronger and more selective TREK-1 inhibition than spadin, less immobility in the forced-swim test, a shorter latency to feed after four days, more neurogenesis and synapse-marker expression, and action lasting up to about 23 hours in mice versus about 7 hours for spadin.
Limits & context
Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming PE-22-28 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Search additional PubMed records ↗

Risks & interactions

Unapproved spadin-derived peptide tested only in cells and mice; there are no published human safety studies, so its risks are unknown.

Human safety data: None

No published human studies were found. The only featured work is from the group that discovered spadin. TREK-1 channels occur in many tissues, so effects outside the brain, long-term exposure and interactions are unknown.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Shortened spadin analogs: TREK-1 inhibition and antidepressant activity (2017) ↗

Safety & what remains unknown

The publication does not include a human safety assessment. TREK-1 channels occur in many tissues, so effects outside the brain, long-term exposure and interactions remain unknown.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Evidence boundaries

Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This profile covers preclinical neuroscience research. PE-22-28 has no approved medical use, and no published human trials were found when this page was checked.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

Spadin and PE-22-28 block TREK-1, a potassium channel linked to mood regulation in animal research. In engineered human cells, PE-22-28 blocked TREK-1 at a far lower concentration than spadin, and its effect lasted longer in mice. Blocking a channel and changing mouse behavior do not show an antidepressant effect in humans.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Questions worth asking

  • Has PE-22-28 been tested in people?
  • What material, population, and route were actually studied?
  • Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Has PE-22-28 been tested in people?

Not in the publications checked for this page. Its evidence comes from cell and mouse experiments, and mouse behavior tests cannot show that it treats depression in humans.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections